Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirbanibulin in Superficial Basal Cell Carcinoma
NCT06112522Phase 2Recruiting
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- Feb 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tirbanibulin in basal cell carcinoma (BCC), sponsored by Centre Hospitalier Universitaire de Nice. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 17 months. Started Feb 2024; status: recruiting.
02
Drugs
tirbanibulin
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT06112522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06112522.